高危局限性上尿路尿路上皮癌的新辅助化疗:2期试验最终长期结局与扩展队列
本研究报道了高危非转移性上尿路尿路上皮癌(UTUC)患者接受吉西他滨联合分次顺铂新辅助化疗(NAC)的长期肿瘤学结局。在57例试验队列中,中位随访5.4年,7年无病生存(DFS)率60%、癌症特异性生存(CSS)率77%、总生存(OS)率72%;NAC应答者7年DFS、CSS和OS均显著优于无应答者。扩展队列(n=126)结果相似,支持将NAC纳入高危非转移性UTUC的治疗范式。
要点
- 高危非转移性UTUC患者接受NAC后7年DFS率60%、CSS率77%、OS率72%。
- NAC应答者7年DFS(78% vs 31%)、CSS(90% vs 56%)、OS(87% vs 48%)均显著优于无应答者。
- 扩展队列(n=126)结果与试验队列相似,支持NAC用于高危非转移性UTUC。
核心结论
- 长期随访数据支持将新辅助化疗(NAC)纳入高危非转移性上尿路尿路上皮癌(UTUC)的治疗范式。
- NAC应答与显著更优的DFS、CSS和OS相关,但膀胱无复发生存(B-RFS)与NAC应答无关。
研究设计与样本
- 前瞻性、多中心、2期临床试验(试验队列n=57)及扩展队列(额外69例,总计n=126)的高危非转移性UTUC患者。
- 患者接受4周期吉西他滨联合分次顺铂NAC后行根治性手术。
- 主要分析为试验队列按病理应答分层,次要分析为扩展队列。
主要发现
- 试验队列存活患者中位随访5.4年(四分位距4.6-7.5),期间发生20例DFS事件、11例CSS事件和18例OS事件。
- 估计7年DFS率为60%,CSS率为77%,OS率为72%。
- NAC应答者7年DFS为78% vs 31%(log-rank p < 0.001),CSS为90% vs 56%(log-rank p = 0.002),OS为87% vs 48%(log-rank p < 0.001)。
- 扩展队列126例接受NAC患者结果相似;B-RFS与NAC应答无关。
关键数值与推荐
- 病理应答定义为<ypT2N0,试验队列57例中应答率为63%。
- NAC方案为吉西他滨联合分次顺铂,共4周期。
临床怎么用
- 对于高危非转移性UTUC,可考虑在根治性手术前给予吉西他滨联合分次顺铂新辅助化疗。
- NAC应答者长期生存获益显著,应答状态可用于预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously reported results from a prospective, multicenter, phase 2 trial that demonstrated a pathologic response rate (<ypT2N0) of 63% among 57 patients with high-risk nonmetastatic upper tract urothelial carcinoma (UTUC) treated with four cycles of neoadjuvant chemotherapy (NAC) comprising gemcitabine and split-dose cisplatin. Here we report updated long-term oncologic outcomes. Outcomes included disease-free survival (DFS, non-urothelial recurrence or death from UTUC), cancer-specific survival (CSS), overall survival (OS), and bladder recurrence-free survival (B-RFS), stratified by pathologic response to NAC in the trial cohort alone (primary analysis) and in an expanded cohort including 69 additional patients (total n = 126) with high-risk nonmetastatic UTUC who received NAC followed by definitive surgery at our institution (secondary analysis). Median follow-up among surviving trial patients was 5.4 yr (interquartile range 4.6-7.5), during which 20 DFS, 11 CSS, and 18 OS events occurred. Estimated 7-yr survival rates were 60% for DFS, 77% for CSS, and 72% for OS. Responders to NAC experienced superior 7-yr DFS (78% vs 31%; log-rank p < 0.001), CSS (90% vs 56%; log-rank p = 0.002), and OS (87% vs 48%; log-rank p < 0.001). Findings were similar in the expanded cohort of 126 patients treated with NAC. B-RFS was not associated with response to NAC. These data support incorporation of NAC in the treatment paradigm for high-risk nonmetastatic UTUC.
引用
- Jayalath VH, Assel M, Iyer G, et al. Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort. Eur Urol. 2025. PMID: 41006098. doi:10.1016/j.eururo.2025.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。